https://www.selleckchem.com/products/E7080.html
BACKGROUND AIMS Check point inhibitors (CPI) have improved survival of oncology patients but adverse effects that mimic autoimmune disorders have been reported. Our aim was describe the characteristics of immune-related hepatitis (irH) and prognosis, and compared them to those of patients with autoimmune hepatitis (AIH). METHODS this a retrospective study including all grade ≥ 3 (severe) irH diagnosed among 414 patients treated with CPI from 2016 to 2018. RESULTS 28 cases of severe irH were recorded 10 on anti-CTLA-4 ± anti-PD1/PD-L
Like
Comment
Share
